

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

ESPS manuscript NO: 28870

Title: Place of technosphere inhaled insulin in treatment of diabetes

Reviewer's code: 01424366

Reviewer's country: Canada

Science editor: Fang-Fang Ji

Date sent for review: 2016-07-21 14:18

Date reviewed: 2016-08-02 23:04

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The review is thorough and is well written. The main shortcoming is that inhaled insulin is not commonly prescribed compared to injected forms, and technosphere-administered inhaled insulin even less so. As the major drive of technology at present is towards CGM and pump algorithms I think the review will reinforce opinion that inhaled insulins are not the way to go for the vast majority of patients. There is a place for such a report though. It is mentioned that a major shortcoming of TI is coughing, and that 40% of insulin is wasted and never absorbed as it is lost to the gut. This seems to be an important economic argument for not using TI. Some mention of economic modelling of TI vs. injection of rapid insulins or pumps would be useful. Another issue with inhaled insulin is that it is unreliable when patients are congested and dosage becomes guess work. Presumably there are recommendations around this.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

ESPS manuscript NO: 28870

Title: Place of technosphere inhaled insulin in treatment of diabetes

Reviewer's code: 00504962

Reviewer's country: Japan

Science editor: Fang-Fang Ji

Date sent for review: 2016-07-21 14:18

Date reviewed: 2016-07-30 23:10

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

This is minireview regarding the place of technosphere inhaled insulin in treatment of diabetes. The topic must be important in the future. 1.Please describe the possibility of inhaled insulin to adolescents. 2.High cost is one of the limitation. Please describe the point in greater detail.